Selected research
Industry Research
Oligonucleotide CDMO Industry Research Report 2026
Market perspective
The global Oligonucleotide CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Oligonucleotide CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oligonucleotide CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oligonucleotide CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oligonucleotide CDMO include Agilent, ST Pharm, Bachem, BioSpring, Creative Biogene, Sylentis, Ajinomoto Bio-Pharma, EUROAPI and Veliter, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Oligonucleotide CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oligonucleotide CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oligonucleotide CDMO Market by Company
Agilent
ST Pharm
Bachem
BioSpring
Creative Biogene
Sylentis
Ajinomoto Bio-Pharma
EUROAPI
Veliter
PolyPeptide Group
CordenPharma
Thermofischer
Bio Basic
Genscript
Cytiva
ScinoPharm
CBL
Piramal Pharma
CPC Scientific
Eurogentec
Cambrex
WuXi STA
Oligonucleotide CDMO Segment by Type
APIs and Intermediates
FDF
Oligonucleotide CDMO Segment by Application
Pharmaceutical and Biotechnology Companies
Research Institutes
Others
Oligonucleotide CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oligonucleotide CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- APIs and Intermediates
- FDF
Applications
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
Companies covered
- Agilent
- ST Pharm
- Bachem
- BioSpring
- Creative Biogene
- Sylentis
- Ajinomoto Bio-Pharma
- EUROAPI
- Veliter
- PolyPeptide Group
- CordenPharma
- Thermofischer
- Bio Basic
- Genscript
- Cytiva
- ScinoPharm
- CBL
- Piramal Pharma
- CPC Scientific
- Eurogentec
- Cambrex
- WuXi STA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oligonucleotide CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 APIs and Intermediates
- 2.2.3 FDF
- 2.3 Oligonucleotide CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical and Biotechnology Companies
- 2.3.3 Research Institutes
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Oligonucleotide CDMO Breakdown Data by Type
- 3.1 Global Oligonucleotide CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Oligonucleotide CDMO Forecasted Market Size by Type (2027-2032)
4 Oligonucleotide CDMO Breakdown Data by Application
- 4.1 Global Oligonucleotide CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Oligonucleotide CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oligonucleotide CDMO Market Perspective (2021-2032)
- 5.2 Global Oligonucleotide CDMO Growth Trends by Region
- 5.2.1 Global Oligonucleotide CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oligonucleotide CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Oligonucleotide CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Oligonucleotide CDMO Market Dynamics
- 5.3.1 Oligonucleotide CDMO Industry Trends
- 5.3.2 Oligonucleotide CDMO Market Drivers
- 5.3.3 Oligonucleotide CDMO Market Challenges
- 5.3.4 Oligonucleotide CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oligonucleotide CDMO Players by Revenue
- 6.1.1 Global Top Oligonucleotide CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Oligonucleotide CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Oligonucleotide CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oligonucleotide CDMO Head Office and Area Served
- 6.4 Global Oligonucleotide CDMO Players, Product Type & Application
- 6.5 Global Oligonucleotide CDMO Manufacturers Established Date
- 6.6 Global Oligonucleotide CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oligonucleotide CDMO Market Size (2021-2032)
- 7.2 North America Oligonucleotide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oligonucleotide CDMO Market Size by Country (2021-2026)
- 7.4 North America Oligonucleotide CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oligonucleotide CDMO Market Size (2021-2032)
- 8.2 Europe Oligonucleotide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oligonucleotide CDMO Market Size by Country (2021-2026)
- 8.4 Europe Oligonucleotide CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oligonucleotide CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Oligonucleotide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oligonucleotide CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oligonucleotide CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oligonucleotide CDMO Market Size (2021-2032)
- 10.2 South America Oligonucleotide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oligonucleotide CDMO Market Size by Country (2021-2026)
- 10.4 South America Oligonucleotide CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oligonucleotide CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Oligonucleotide CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oligonucleotide CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oligonucleotide CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Agilent
- 12.1.1 Agilent Company Information
- 12.1.2 Agilent Business Overview
- 12.1.3 Agilent Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.1.4 Agilent Oligonucleotide CDMO Product Portfolio
- 12.1.5 Agilent Recent Developments
- 12.2 ST Pharm
- 12.2.1 ST Pharm Company Information
- 12.2.2 ST Pharm Business Overview
- 12.2.3 ST Pharm Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.2.4 ST Pharm Oligonucleotide CDMO Product Portfolio
- 12.2.5 ST Pharm Recent Developments
- 12.3 Bachem
- 12.3.1 Bachem Company Information
- 12.3.2 Bachem Business Overview
- 12.3.3 Bachem Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.3.4 Bachem Oligonucleotide CDMO Product Portfolio
- 12.3.5 Bachem Recent Developments
- 12.4 BioSpring
- 12.4.1 BioSpring Company Information
- 12.4.2 BioSpring Business Overview
- 12.4.3 BioSpring Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.4.4 BioSpring Oligonucleotide CDMO Product Portfolio
- 12.4.5 BioSpring Recent Developments
- 12.5 Creative Biogene
- 12.5.1 Creative Biogene Company Information
- 12.5.2 Creative Biogene Business Overview
- 12.5.3 Creative Biogene Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.5.4 Creative Biogene Oligonucleotide CDMO Product Portfolio
- 12.5.5 Creative Biogene Recent Developments
- 12.6 Sylentis
- 12.6.1 Sylentis Company Information
- 12.6.2 Sylentis Business Overview
- 12.6.3 Sylentis Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.6.4 Sylentis Oligonucleotide CDMO Product Portfolio
- 12.6.5 Sylentis Recent Developments
- 12.7 Ajinomoto Bio-Pharma
- 12.7.1 Ajinomoto Bio-Pharma Company Information
- 12.7.2 Ajinomoto Bio-Pharma Business Overview
- 12.7.3 Ajinomoto Bio-Pharma Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.7.4 Ajinomoto Bio-Pharma Oligonucleotide CDMO Product Portfolio
- 12.7.5 Ajinomoto Bio-Pharma Recent Developments
- 12.8 EUROAPI
- 12.8.1 EUROAPI Company Information
- 12.8.2 EUROAPI Business Overview
- 12.8.3 EUROAPI Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.8.4 EUROAPI Oligonucleotide CDMO Product Portfolio
- 12.8.5 EUROAPI Recent Developments
- 12.9 Veliter
- 12.9.1 Veliter Company Information
- 12.9.2 Veliter Business Overview
- 12.9.3 Veliter Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.9.4 Veliter Oligonucleotide CDMO Product Portfolio
- 12.9.5 Veliter Recent Developments
- 12.10 PolyPeptide Group
- 12.10.1 PolyPeptide Group Company Information
- 12.10.2 PolyPeptide Group Business Overview
- 12.10.3 PolyPeptide Group Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.10.4 PolyPeptide Group Oligonucleotide CDMO Product Portfolio
- 12.10.5 PolyPeptide Group Recent Developments
- 12.11 CordenPharma
- 12.11.1 CordenPharma Company Information
- 12.11.2 CordenPharma Business Overview
- 12.11.3 CordenPharma Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.11.4 CordenPharma Oligonucleotide CDMO Product Portfolio
- 12.11.5 CordenPharma Recent Developments
- 12.12 Thermofischer
- 12.12.1 Thermofischer Company Information
- 12.12.2 Thermofischer Business Overview
- 12.12.3 Thermofischer Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.12.4 Thermofischer Oligonucleotide CDMO Product Portfolio
- 12.12.5 Thermofischer Recent Developments
- 12.13 Bio Basic
- 12.13.1 Bio Basic Company Information
- 12.13.2 Bio Basic Business Overview
- 12.13.3 Bio Basic Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.13.4 Bio Basic Oligonucleotide CDMO Product Portfolio
- 12.13.5 Bio Basic Recent Developments
- 12.14 Genscript
- 12.14.1 Genscript Company Information
- 12.14.2 Genscript Business Overview
- 12.14.3 Genscript Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.14.4 Genscript Oligonucleotide CDMO Product Portfolio
- 12.14.5 Genscript Recent Developments
- 12.15 Cytiva
- 12.15.1 Cytiva Company Information
- 12.15.2 Cytiva Business Overview
- 12.15.3 Cytiva Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.15.4 Cytiva Oligonucleotide CDMO Product Portfolio
- 12.15.5 Cytiva Recent Developments
- 12.16 ScinoPharm
- 12.16.1 ScinoPharm Company Information
- 12.16.2 ScinoPharm Business Overview
- 12.16.3 ScinoPharm Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.16.4 ScinoPharm Oligonucleotide CDMO Product Portfolio
- 12.16.5 ScinoPharm Recent Developments
- 12.17 CBL
- 12.17.1 CBL Company Information
- 12.17.2 CBL Business Overview
- 12.17.3 CBL Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.17.4 CBL Oligonucleotide CDMO Product Portfolio
- 12.17.5 CBL Recent Developments
- 12.18 Piramal Pharma
- 12.18.1 Piramal Pharma Company Information
- 12.18.2 Piramal Pharma Business Overview
- 12.18.3 Piramal Pharma Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.18.4 Piramal Pharma Oligonucleotide CDMO Product Portfolio
- 12.18.5 Piramal Pharma Recent Developments
- 12.19 CPC Scientific
- 12.19.1 CPC Scientific Company Information
- 12.19.2 CPC Scientific Business Overview
- 12.19.3 CPC Scientific Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.19.4 CPC Scientific Oligonucleotide CDMO Product Portfolio
- 12.19.5 CPC Scientific Recent Developments
- 12.20 Eurogentec
- 12.20.1 Eurogentec Company Information
- 12.20.2 Eurogentec Business Overview
- 12.20.3 Eurogentec Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.20.4 Eurogentec Oligonucleotide CDMO Product Portfolio
- 12.20.5 Eurogentec Recent Developments
- 12.21 Cambrex
- 12.21.1 Cambrex Company Information
- 12.21.2 Cambrex Business Overview
- 12.21.3 Cambrex Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.21.4 Cambrex Oligonucleotide CDMO Product Portfolio
- 12.21.5 Cambrex Recent Developments
- 12.22 WuXi STA
- 12.22.1 WuXi STA Company Information
- 12.22.2 WuXi STA Business Overview
- 12.22.3 WuXi STA Revenue in Oligonucleotide CDMO Business (2021-2026)
- 12.22.4 WuXi STA Oligonucleotide CDMO Product Portfolio
- 12.22.5 WuXi STA Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst